Monopar Therapeutics (MNPR)
Nasdaq · Pharmaceutical Preparations · Manufacturing · CIK 1645469 · fiscal year ends in Dec
Closing price $72.01 on 29 Oct 2026; 52-week range $50.12 to $123.84.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Market value
- $483.3M
- Cash
- $52.8M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 6.7M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $0 | -$16.7M | -$13.7M | -$1.85 | – | 10-K filed 27 Mar 2026 |
| FY2024 | 31 Dec 2024 | $0 | -$16.2M | -$15.6M | -$4.11 | – | 10-K filed 31 Mar 2025 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $0 | -$5.3M | -$0.62 |
| Q1 FY2026 | 31 Mar 2026 | $0 | -$3.9M | -$0.46 |
Company events
The newest 8-K filings of 118 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 12 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 22 Jul 2026 | 8-K | Investor update | 7.01, 9.01 |
| 30 Jun 2026 | 8-K | Investor update | 7.01, 9.01 |
| 26 Jun 2026 | 8-K | Investor update | 7.01, 9.01 |
| 23 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 29 May 2026 | 8-K | Investor update | 7.01, 9.01 |
| 19 May 2026 | 8-K | Investor update | 7.01, 9.01 |
| 14 May 2026 | 8-K | Results | 2.02, 9.01 |
| 20 Apr 2026 | 8-K | Investor update | 7.01, 9.01 |
| 27 Mar 2026 | 8-K | Results | 2.02, 9.01 |
| 2 Mar 2026 | 8-K | Investor update | 7.01, 9.01 |
| 13 Nov 2025 | 8-K | Results | 2.02, 9.01 |
Every filing
The newest filings with the SEC of 240 held.
| Filed | Form | Period |
|---|---|---|
| 12 Aug 2026 | 8-K | 12 Aug 2026 |
| 12 Aug 2026 | 10-Q | 30 Jun 2026 |
| 22 Jul 2026 | S-8 POS | – |
| 22 Jul 2026 | S-8 POS | – |
| 22 Jul 2026 | S-8 POS | – |
| 22 Jul 2026 | S-8 POS | – |
| 22 Jul 2026 | S-8 | – |
| 22 Jul 2026 | 8-K | 22 Jul 2026 |
| 30 Jun 2026 | 8-K | 30 Jun 2026 |
| 26 Jun 2026 | 8-K | 26 Jun 2026 |
| 23 Jun 2026 | 8-K | 22 Jun 2026 |
| 29 May 2026 | 8-K | 29 May 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 1 Oct 2026 | Starr Christopher M, Director | Sale under a trading plan | 4,631 | $78.09 | $361.6K | 8,942 | 5 Oct 2026 |
| 1 Oct 2026 | Starr Christopher M, Director | Sale under a trading plan | 2,970 | $78.82 | $234.1K | 5,972 | 5 Oct 2026 |
| 1 Oct 2026 | Starr Christopher M, Director | Sale under a trading plan | 799 | $79.67 | $63.7K | 5,173 | 5 Oct 2026 |
| 24 Sep 2026 | Robinson Chandler, Chief Executive Officer | Sale under a trading plan | 10,450 | $87.15 | $910.7K | 117,873 | 28 Sep 2026 |
| 24 Sep 2026 | Robinson Chandler, Chief Executive Officer | Sale under a trading plan | 9,638 | $87.96 | $847.8K | 108,235 | 28 Sep 2026 |
| 24 Sep 2026 | Robinson Chandler, Chief Executive Officer | Sale under a trading plan | 8,368 | $88.97 | $744.5K | 99,867 | 28 Sep 2026 |
| 24 Sep 2026 | Robinson Chandler, Chief Executive Officer | Sale under a trading plan | 600 | $89.79 | $53.9K | 99,267 | 28 Sep 2026 |
| 26 Aug 2026 | Rioux Patrice, Insider | Sale under a trading plan | 1 | $111.26 | $111 | 5,065 | 27 Aug 2026 |
| 26 Aug 2026 | Tsuchimoto Kim R, Director | Sale under a trading plan | 485 | $108.83 | $52.8K | 11,001 | 27 Aug 2026 |
| 26 Aug 2026 | Tsuchimoto Kim R, Director | Sale under a trading plan | 615 | $109.56 | $67.4K | 10,386 | 27 Aug 2026 |
| 26 Aug 2026 | Tsuchimoto Kim R, Director | Sale under a trading plan | 700 | $110.65 | $77.5K | 9,686 | 27 Aug 2026 |
| 26 Aug 2026 | Tsuchimoto Kim R, Director | Sale under a trading plan | 1,098 | $111.84 | $122.8K | 8,588 | 27 Aug 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 1 Oct 2026 | CHRISTOPHER STARR, Director | 16,800 | $1.3M | 1 Oct 2026 |
| 24 Sep 2026 | CHANDLER ROBINSON, Director, Officer | 29,056 | $2.6M | 24 Sep 2026 |
| 26 Aug 2026 | PATRICE RIOUX, Acting Chief Medical Officer | 1 | $111 | 26 Aug 2026 |
| 26 Aug 2026 | KIM TSUCHIMOTO, Director | 8,180 | $906.5K | 26 Aug 2026 |
| 25 Aug 2026 | RAYMOND WILLIAM ANDERSON, Director | 6,284 | $699.8K | 25 Aug 2026 |
| 7 Jul 2026 | Arthur Klausner, Employer | 5,000 | $485.3K | 7 Jul 2026 |
| 19 Dec 2025 | Arthur Klausner, Board Member | 5,121 | $343.9K | 18 Dec 2025 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 27 Oct 2026 | BlackRock, Inc. | 13G | 5.03% | 338.1K |
| 12 Aug 2026 | Saturn V Capital Management LP | 13G amended | 4.7% | 313.4K |
| 12 Aug 2026 | Adage Capital Management, L.P. | 13G amended | 4.76% | 324.2K |
| 15 May 2026 | Saturn V Capital Management LP | 13G | 5.2% | 345.6K |
| 13 May 2026 | Adage Capital Management, L.P. | 13G amended | 6.23% | 424.2K |
| 17 Feb 2026 | RA Capital Management, L.P. | 13G amended | 9.9% | 667.6K |
| 6 Feb 2026 | AstraZeneca PLC | 13G amended | 7.8% | 522.7K |
| 30 Jan 2026 | Tactic Pharma LLC | 13D amended | 4.5% | 307.4K |
| 14 Nov 2025 | JANUS HENDERSON GROUP PLC | 13G amended | 19.5% | 1.3M |
| 14 Nov 2025 | RA Capital Management, L.P. | 13G amended | 9.9% | 742.9K |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 1.1M | +3.9% | 7.14 |
| 30 Sep 2026 | 1.1M | +28.67% | 6.02 |
| 15 Sep 2026 | 844.2K | -0.96% | 7.2 |
| 31 Aug 2026 | 852.4K | -3.92% | 4.54 |
| 14 Aug 2026 | 887.2K | -16.7% | 3.48 |
| 31 Jul 2026 | 1.1M | -21.7% | 3.4 |
| 15 Jul 2026 | 1.4M | -10.49% | 5.94 |
| 30 Jun 2026 | 1.5M | -2.47% | 8.61 |
Funds that hold it
From each fund's latest Form 13F.
109 funds held it at 30 Jun 2026: 58 added and 24 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Jupiter Topco LLC | 1,312,129 | $121.7M | – |
| Ra Capital Management, L.P. | 667,207 | $61.8M | 0 |
| BlackRock, Inc. | 348,819 | $32.3M | +32,252 |
| Deerfield Management Company, L.P. | 323,745 | $30.0M | 0 |
| Saturn V Capital Management LP | 311,976 | $28.9M | -33,650 |
| Siren, L.L.C. | 270,118 | $25.0M | 0 |
| ADAR1 Capital Management, LLC | 217,595 | $20.1M | -46,683 |
| Polar Capital Holdings Plc | 214,469 | $19.9M | -12,057 |
| Vanguard Capital Management LLC | 209,711 | $19.4M | -8,752 |
| Adage Capital Partners GP, L.l.c. | 209,195 | $19.4M | -100,000 |
Peers
Companies in the same industry.
- Eli Lilly & Co. (LLY): revenue $86.5B, market value $1.29T
- Johnson & Johnson (JNJ): revenue $99.3B, market value $662.4B
- AbbVie Inc. (ABBV): revenue $64.4B, market value $513.9B
- Merck & Co., Inc. (MRK): revenue $66.6B, market value $361.0B
- Novartis AG (NVS): revenue $54.5B, market value $307.3B
- AstraZeneca PLC (AZN): revenue $58.7B, market value $270.6B
- Abbott Laboratories (ABT): revenue $46.6B, market value $180.9B
- Novo Nordisk A/S (NVO): revenue $46.8B, market value $174.8B
- Pfizer Inc. (PFE): revenue $63.7B, market value $170.7B
- Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $136.8B